2026 oncology meetings

SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.

SITC

SITC Annual Meeting 2026

4–8 Nov 2026, Phoenix

verified abstracts in 1 area

ESMO

ESMO Congress 2026

23–27 Oct 2026, Madrid

146

verified abstracts in 8 areas

ASCO

ASCO Annual Meeting 2026

29 May – 2 Jun 2026, Chicago

verified abstracts in 1 area

AACR

AACR Annual Meeting 2026

17–22 Apr 2026, San Diego

verified abstracts in 1 area

ASH

ASH Annual Meeting 2026

12–15 Dec 2026, New Orleans

verified abstracts in 4 areas

175 of 285 verified abstracts were confirmed on a page we fetched ourselves

Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.

Found on the cited source pageFound on a second fetched pageMatches only the excerpt saved from a page we could not re-fetch

Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.

ASCO Annual Meeting 2026

29 May – 2 Jun 2026, Chicago · Journal of Clinical Oncology 44 (16_suppl; LBAs in 17_suppl)

All 7,222 regular abstracts and 60 late-breaking abstracts have JCO supplement DOIs in Crossref.

Non-small cell lung cancer

13 verified · pulled 2026-11-11Open in Non-small cell lung cancer →

LBA4
Presidential
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Chen Zhiwei (presented by Shun Lu, MD, PhD)HARMONi-6NCT05840016ivonescimabtislelizumabpaclitaxelcarboplatin
Verified on source pageasco.org
LBA1510
Late-breaking
Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial.
Nandini Sharrel Menon (presented by Nandini Sharrel Menon, MD, DNB, MBBS)pembrolizumabpemetrexedpaclitaxelcarboplatin
Verified on source pageasco.org
LBA8500
Late-breaking
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
John V. HeymachWU-KONG28NCT05668988sunvozertinibplatinum-based chemotherapy
Verified on a second sourceascopubs.org
8000
Oral presentation
Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
ECOG-ACRIN EA5142; ALCHEMISTNCT02595944nivolumab
Verified on source pageascopubs.org
8001
Oral presentation
Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.
Alliance A081105NCT02193282erlotinib
Verified on a second sourceascopubs.org
8002
Oral presentation
Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN).
LORINlorlatinib
Verified on a second sourceascopubs.org
8501
Oral presentation
Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.
Joel W. Neal (presented by Joel W. Neal, MD, PhD)CHRYSALIS-2NCT04077463amivantamablazertinib
Verified on a second sourcemeetings.asco.org
8502
Oral presentation
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
CROWNNCT03052608lorlatinibcrizotinib
Verified on a second sourceascopubs.org
8503
Oral presentation
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
Jessica Jiyeong LinALKOVE-1neladalkib
Verified on a second sourceascopubs.org
8504
Oral presentation
Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.
Sanjay Popat (presented by Sanjay Popat, PhD, FRCP)AcceleRET-Lungpralsetinib
Verified on a second sourcemeetings.asco.org
8505
Oral presentation
Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).
Qing Zhou (presented by Qing Zhou, MD, PhD)NCT05265091lunbotinib
Verified on a second sourceasco.org
8506
Oral presentation
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
Caicun ZhouOptiTROP-Lung05NCT06448312sacituzumab tirumotecan (sac-TMT)pembrolizumab
Verified on a second sourceascopubs.org
8624
Oral presentation
Wait or treat? managing asymptomatic brain metastases in oncogene-mutated NSCLC: Results of a phase-III randomized controlled trial.
NCT05236946
Verified on a second sourcemeetings.asco.org